Abstract
Migraine headaches have a female predominance with a peak in prevalence in the third and fourth decades of life. Women of reproductive age are liable to develop their first migraine while pregnant or exhibit changes in the character, frequency or severity of their headaches during pregnancy and the puerperium. The purpose of this Review is to examine the pathophysiology underlying the development of migraine headaches and the association of this pathophysiology with pregnancy-related complications. We also discuss the diagnosis and management of migraine headaches that precede pregnancy or develop de novo during pregnancy, placing an emphasis on the distinction between primary migraine headache and headache secondary to pre-eclampsia—a relatively frequent complication of pregnancy and the puerperium. We present the case of a woman with a history of migraine headaches before pregnancy, whose symptoms progressed during pregnancy in part because of increasing exposure to narcotic medications. We also review the options for migraine evaluation and treatment, and provide an overview of the risks associated with the different treatment options.
Key Points
-
Migraines affect up to 18% of pregnant women
-
In most cases, migraine has been diagnosed before pregnancy
-
Migraines need to be differentiated from other complications associated with or resulting from pregnancy and the puerperium
-
Differentiation of migraine from pre-eclampsia-associated headache is important because migraine does not necessitate emergent delivery
-
Persistent headache in the context of pre-eclampsia can be an indication for emergent delivery to prevent further maternal complications
-
The main precept for the management of migraines during pregnancy is to use the smallest amount of medication necessary for adequate pain prevention and control
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lipton, R., Stewart, W., Diamond, S., Diamond, M. L. & Reed, M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 41, 646–657 (2001).
Somerville, B. W. The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology 22, 355–365 (1972).
Menon, R. & Bushnell, C. D. Headache and pregnancy. Neurologist 14, 108–119 (2008).
Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 24 (Suppl. 1), 9–160 (2004).
Welch, K. M., D'Andrea, G., Tepley, N., Barkley, G. & Ramadan, N. M. The concept of migraine as a state of central neuronal hyperexcitability. Neurol. Clin. 8, 817–828 (1990).
Rothrock, J. F. “Outside-in” vs “inside-out”: revisiting migraine's vascular hypothesis. Headache 48, 1409–1410 (2008).
Silberstein, S. D. Migraine. Lancet 363, 381–391 (2004).
Goadsby, P. & Edvinsson, L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol. 33, 48–56 (1993).
Stang, P. et al. Headache, cerebrovascular symptoms, and stroke: the Atherosclerosis Risk in Communities Study. Neurology 64, 1573–1577 (2005).
Kurth, T. et al. Migraine, headache, and the risk of stroke in women. Neurology 64, 1020–1026 (2005).
Gupta, V. Silent or non-clinical infarct-like lesions in the posterior circulation territory in migraine: brain hypoperfusion or hyperperfusion? Brain 129, E39 (2006).
Calabrese, L. H., Dodick, D. W., Schwedt, T. J. & Singhal, A. B. Narrative review: reversible cerebral vasoconstriction syndromes. Ann. Intern. Med. 146, 34–44 (2007).
Tietjen, G. E. Migraine as a systemic disorder. Neurology 68, 1555–1556 (2007).
Lance, J. W. & Anthony, M. Some clinical aspects of migraine: a prospective survey of 500 patients. Arch. Neurol. 15, 356–361 (1966).
Kelman, L. Women's issues of migraine in tertiary care. Headache 44, 2–7 (2004).
Marcus, D. A., Scharff, L. & Turk, D. C. Longitudinal prospective study of headache during pregnancy and postpartum. Headache 39, 625–632 (1999).
Sances, G. et al. Course of migraine during pregnancy and postpartum: a prospective study. Cephalalgia 23, 197–205 (2003).
Scharff, L., Marcus, D. A. & Turk, D. C. Headache during pregnancy and in the postpartum: a prospective study. Headache 37, 203–210 (1997).
Granella, F. et al. Migraine with aura and reproductive life events: a case control study. Cephalalgia 20, 701–707 (2000).
Amir, B. Y. et al. Headaches in women undergoing in vitro fertilization and embryo-transfer treatment. Headache 45, 215–219 (2005).
Parra, J. et al. Migrainous infarction and clomiphene citrate [Spanish]. Rev. Neurol. 42, 572–574 (2006).
Silberstein, S. Headache and female hormones: what you need to know. Curr. Opin. Neurol. 14, 323–333 (2001).
Ertresvåg, J. M., Zwart, J. A., Helde, J., Johnsen, H. & Bovim, G. Headache and transient focal neurological symptoms during pregnancy, a prospective cohort. Acta Neurol. Scand. 111, 233–237 (2005).
Banhidy, F., Acs, N., Horváth-Puhó, E. & Czeizel, A. Pregnancy complications and delivery outcomes in pregnant women with severe migraine Eur. J. Obstet. Gynecol. Reprod. Biol. 134, 157–163 (2006).
Facchinetti, F., Allais, G., D'Amico, R., Benedetto, C. & Volpe, A. The relationship between headache and pre-eclampsia: a case-control study. Eur. J. Obstet. Gynecol. Reprod. Biol. 121, 143–148 (2005).
Adeney, K. Risk of pre-eclampsia in relation to maternal history of migraine headaches. J. Matern. Fetal Neonatal Med. 18, 167–172 (2005).
Maggioni, F., Alessi, C., Maggino, T. & Zanchin, G. Headache during pregnancy. Cephalalgia 17, 765–769 (1997).
Wainscott, G., Volans, G., Sullivan, F. & Wilkinson, M. The outcome of pregnancy in women suffering from migraine. Postgrad. Med. J. 54, 98–102 (1978).
Bushnell, C. D., Jamison, M. G. & James, A. Migraines during pregnancy linked to stroke and vascular diseases: US population based case-control study. BMJ 338, b664 (2009).
Loder, E. Migraine in pregnancy. Semin. Neurol. 27, 425–433 (2007).
Singhal, A. B. & Bernstein, R. A. Postpartum angiopathy and other cerebral vasoconstriction syndromes. Neurocritic. Care 3, 91–97 (2005).
Silberstein, S. Practice Parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55, 754–762 (2000).
Kumar, K. L. & Cooney, T. G. Headaches. Med. Clin. North Am. 79, 261–286 (1995).
Kent, D. L., Haynor, D. R., Longstreth, W. T. & Larson, E. The clinical efficacy of magnetic resonance imaging in neuroimaging. Ann. Intern. Med. 120, 856–871 (1994).
Brent, R. Saving lives and changing family histories: appropriate counseling of pregnant women and men and women of reproductive age, concerning the risk of diagnostic radiation exposures during and before pregnancy. Am. J. Obstet. Gynecol. 200, 4–24 (2009).
Gorson, R. O. Report No. 054—Medical radiation exposure of pregnant and potentially pregnant women (National Council on Radiation Protection and Measurements, Bethesda, MD, 1977).
Lin, S. P. & Brown, J. J. MR contrast agents: physical and pharmacologic basics. J. Magn. Reson. Imaging 25, 884–899 (2007).
Kanal, E. et al. ACR guidance document for safe MR practices: 2007. AJR Am. J. Roentgenol. 188, 1447–1474 (2007).
Tepel, M. et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N. Engl. J. Med. 343, 180–184 (2000).
Rao, Q. A. & Newhouse, J. H. Risk of nephropathy after intravenous administration of contrast material: a critical literature analysis. Radiology 239, 392–397 (2006).
Webb, J., Thomsen, H., Morcos, S. & Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). The use of iodinated and gadolinium contrast media during pregnancy and lactation. Eur. Radiol. 15, 1234–1240 (2005).
Cunningham, F. et al. Williams Obstetrics 22nd edn 567–618 (McGraw-Hill Professional, New York, 2001).
[No authors listed] Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am. J. Obstet. Gynecol. 183, S1–S22 (2000).
Sanchez, S. E., Qiu, C., Williams, M. A., Lam, N. & Sorensen, T. K. Headaches and migraines are associated with an increased risk of pre-eclampsia in Peruvian women. Am. J. Hypertens. 21, 360–364 (2008).
Adeney, K. L. & Williams, M. A. Migraine headaches and pre-eclampsia: an epidemiologic review. Headache 46, 794–803 (2006).
Zhou, Y. et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe pre-eclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am. J. Pathol. 160, 1405–1423 (2002).
Sibai, B. et al. Maternal plasma concentrations of the soluble tumor necrosis factor receptor 2 are increased prior to the diagnosis of pre-eclampsia. Am. J. Obstet. Gynecol. 200, e1–8 (2009).
Welch, K. M. Contemporary concepts of migraine pathogenesis. Neurology 61 (Suppl. 4), S2–S8 (2003).
Hayashi, M. et al. Characterization of five marker levels of the hemostatic system and endothelial status in normotensive pregnancy and pre-eclampsia. Eur. J. Haematol. 69, 297–302 (2002).
Wilson, B. J. et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ 326, 845–852 (2003).
Brown, D. W. et al. Pre-eclampsia and the risk of ischemic stroke among young women: results from the Stroke Prevention in Young Women Study. Stroke 37, 1055–1059 (2006).
Fox, A. W., Diamond, M. L. & Spierings, E. L. Migraine during pregnancy: options for therapy. CNS Drugs 19, 465–481 (2005).
Food and Nutrition Board, Institute of Medicine & National Academy of Sciences. Dietary reference intakes for thiamine, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. (National Academy Press, Washington DC, 1998).
Centers for Disease Control (CDC). Use of folic acid for prevention of spina bifida and other neural tube defects–1983-1991. MMWR Morb. Mortal. Wkly Rep. 40, 513–516 (1991).
Pitkin, R. M. Folate and neural tube defects. Am. J. Clin. Nutr. 85, S285–S288 (2007).
Hunt, S. et al. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 71, 272–276 (2008).
Friedman, J. et al. Potential human teratogenicity of frequently prescribed drugs. Obstet. Gynecol. 75, 594–599 (1990).
Addis, A., Sharabi, S. & Bonati, M. Risk classification systems for drug use during pregnancy: are they a reliable source of information? Drug Saf. 23, 245–253 (2000).
Silberstein, S. D. The pharmacology of ergotamine and dihydroergotamine. Headache 37 (Suppl. 1), S15–S25 (1997).
Graham, J. R. & Wolff, H. G. Mechanism of migraine headache and action of ergotamine tartrate. Arch. Neurol. Psych. 39, 737–763 (1938).
Czeizel, A. Teratogenicity of ergotamine. J. Med. Genet. 26, 69–70 (1989).
Hoyer, D. et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 46, 157–203 (1994).
Humphrey, P. P. et al. Preclinical studies on the anti-migraine drug, sumatriptan. Eur. Neurol. 31, 282–290 (1991).
Moskowitz, M. A. Neurogenic versus vascular mechanism of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol. Sci. 13, 307–311 (1992).
Loder, E. Safety of sumatriptan in pregnancy: a review of the data so far. CNS Drugs 17, 1–7 (2003).
Fox, A. W., Chambers, C. & Anderson, P. Evidence-based assessment of pregnancy outcome after sumatriptan exposure. Headache 42, 8–15 (2002).
O'Quinn, S. et al. Pregnancy and perinatal outcomes in migraineurs using sumatriptan: a prospective study. Arch. Gynecol. Obstet. 263, 7–12 (1999).
The Sumatriptan and Naratriptan Pregnancy Registry Interim Report. 1 January 1996 through 30 April 2004 (GlaxoSmithKline Company, Wilmington, NC, 2004).
källén, B. & Lygner, P. E. Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. Headache 41, 351–356 (2001).
Hendricks, S., Smith, J., Moore, D. & Brown, Z. Oligohydramnios associated with prostaglandin synthetase inhibitors in preterm labour. Br. J. Obstet. Gynaecol. 97, 312–316 (1990).
Diener, H., Lampl, C., Reimnitz, P. & Voelker, M. Aspirin in the treatment of acute migraine attacks. Expert Rev. Neurother. 6, 563–573 (2006).
Regal, R. E., Billi, J. E. & Glazer, H. M. Phenothiazine-induced cholestatic jaundice. Clin. Pharm. 6, 787–794 (1987).
Davis, R. L. et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol. Drug Saf. 16, 1086–1094 (2007).
Acknowledgements
Charles P. Vega, University of California, Irvine, CA, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the MedscapeCME-accredited continuing medical education activity associated with this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Contag, S., Mertz, H. & Bushnell, C. Migraine during pregnancy: is it more than a headache?. Nat Rev Neurol 5, 449–456 (2009). https://doi.org/10.1038/nrneurol.2009.100
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2009.100
This article is cited by
-
Headaches during pregnancy and the risk of subsequent stroke
The Journal of Headache and Pain (2023)
-
The Impact of Parental Migraine on Children
Current Pain and Headache Reports (2020)
-
Headache and pregnancy: a systematic review
The Journal of Headache and Pain (2017)
-
Characteristics and diagnoses of acute headache in pregnant women – a retrospective cross-sectional study
The Journal of Headache and Pain (2017)
-
Migraine and preterm birth
Journal of Perinatology (2011)